Nimotuzumab

Nimotuzumab
Product Description

Nimotuzumab binds with intermediate affinity and high specificity to the extracellular domain of EGFR and blocks the binding of the EGF to its receptor and inhibits tumor cell growth. The molecule induces cell lysis through ADCC mechanism. Nimotuzumab provides vaccinal effect that induce memory T-cell to fight EGFR. 
It is listed in India Medical Guideline for Head & Neck Cancer treatment, and listed in Indonesia Medical Guideline for GBM treatment. 

Read more Show less

Kalbe

  • Country/Region:
    Indonesia
  • On CPHI since:
    2018
  • Certificates:
    3
  • Employees:
    5000+
Company types
Contract Service
Distributor/Import Export
Licensee
Manufacturer/Innovator
Primary activities
Biopharmaceutical
Contract Manufacturer
Finished Formulation products Distributor/Buyer
Ingredients Distributor/Buyer
Natural Extracts
Out-licensing specialist
Pharmaceutical Company (generic finished products)
View company profile
Categories
more categories Show less
Specifications
  • Selling Points
    Product Performance
More specifications Fewer specifications

Kalbe

  • Country/Region:
    Indonesia
  • On CPHI since:
    2018
  • Certificates:
    3
  • Employees:
    5000+
Company types
Contract Service
Distributor/Import Export
Licensee
Manufacturer/Innovator
Primary activities
Biopharmaceutical
Contract Manufacturer
Finished Formulation products Distributor/Buyer
Ingredients Distributor/Buyer
Natural Extracts
Out-licensing specialist
Pharmaceutical Company (generic finished products)
View company profile

More Products from Kalbe (2)

  • hyfc EPO (long acting)

    Product hyfc EPO (long acting)

    Efesa, is a long-acting Erythropoietin indicated for CKD-induced anemia in dialysis and non-dialysis patients. Efesa is a hybrid Fc of IgG4 and IgD that provides hinge flexibility and long serum half-life without causing toxicity to target cells. Global Phase 3 trial for non-dialysis indication is currentl...
  • Insulin Glargine

    Product Insulin Glargine

    Long-acting basal insulin analogue to treat Type I and II Diabetes Mellitus.

Kalbe resources (1)